AU2002218002A1 - Use of pyridoxamine for the treatment and inhibition of obesity-related complications - Google Patents
Use of pyridoxamine for the treatment and inhibition of obesity-related complicationsInfo
- Publication number
- AU2002218002A1 AU2002218002A1 AU2002218002A AU1800202A AU2002218002A1 AU 2002218002 A1 AU2002218002 A1 AU 2002218002A1 AU 2002218002 A AU2002218002 A AU 2002218002A AU 1800202 A AU1800202 A AU 1800202A AU 2002218002 A1 AU2002218002 A1 AU 2002218002A1
- Authority
- AU
- Australia
- Prior art keywords
- obesity
- related complications
- pyridoxamine
- inhibition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- External Artificial Organs (AREA)
Abstract
The present invention provides methods and pharmaceutical compositions for treating or inhibiting obesity-related complications that comprise administering to an obese subject an amount effective of pyridoxamine to treat or inhibit obesity-related complications selected from the group consisting of hyperlipidemia, renal disease, proliferation or smooth muscle cells in the aorta, coronary artery occlusion, atherosclerosis, hypertension, advanced glycation end-product formation and advanced lipoxidation end-product formation.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24563000P | 2000-11-02 | 2000-11-02 | |
US60/245,630 | 2000-11-02 | ||
US31578901P | 2001-08-29 | 2001-08-29 | |
US60/315,789 | 2001-08-29 | ||
PCT/US2001/045415 WO2002036109A2 (en) | 2000-11-02 | 2001-11-02 | Use of pyridoxamine for the treatment and inhibition of obesity-related complications |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002218002A1 true AU2002218002A1 (en) | 2002-05-15 |
Family
ID=26937355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002218002A Abandoned AU2002218002A1 (en) | 2000-11-02 | 2001-11-02 | Use of pyridoxamine for the treatment and inhibition of obesity-related complications |
Country Status (6)
Country | Link |
---|---|
US (1) | US20020128295A1 (en) |
EP (1) | EP1341532B1 (en) |
AT (1) | ATE333868T1 (en) |
AU (1) | AU2002218002A1 (en) |
DE (1) | DE60121794D1 (en) |
WO (1) | WO2002036109A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030146B2 (en) * | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
DK1643999T3 (en) * | 2003-06-20 | 2012-01-02 | Nephrogenex Inc | Pyridoxamine for use in the treatment of diabetic nephropathy in type 2 diabetes |
US20090082407A1 (en) * | 2004-06-18 | 2009-03-26 | Biostratum, Inc. | Pyridoxamine for the Treatment of Diabetic Kidney Disease |
US7214799B2 (en) * | 2004-02-09 | 2007-05-08 | Biostratum, Inc. | Methods for the synthesis of pyridoxamine |
CN100558359C (en) * | 2004-09-06 | 2009-11-11 | 兴和株式会社 | Remedy for glomerular diseae |
DE102004050353A1 (en) * | 2004-10-15 | 2006-04-20 | Basf Ag | Use of stable ammonium salts of lipoic acid for the treatment of diabetic and other disorders |
CA2844150C (en) | 2011-07-12 | 2019-09-03 | Vanderbilt University | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers |
BR112019022523A2 (en) | 2017-04-27 | 2020-05-12 | Vanderbilt University | METHODS FOR TREATING AEROSCLEROSIS WITH GETO-KETOALDEHYDE SEQUESTRANTS |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288716A (en) * | 1987-02-18 | 1994-02-22 | Ulrich Speck | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis |
US6228858B1 (en) * | 1995-09-12 | 2001-05-08 | University Of Kansas Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
WO2000021516A2 (en) * | 1998-10-14 | 2000-04-20 | Kansas University Medical Center Research Institute, Inc. | Methods for inhibiting diabetic complications |
ES2197689T3 (en) * | 1998-10-22 | 2004-01-01 | University Of South Carolina | PROCEDURES TO INHIBIT DIABETIC COMPLICATIONS. |
-
2001
- 2001-11-02 WO PCT/US2001/045415 patent/WO2002036109A2/en active IP Right Grant
- 2001-11-02 AT AT01992569T patent/ATE333868T1/en not_active IP Right Cessation
- 2001-11-02 EP EP01992569A patent/EP1341532B1/en not_active Expired - Lifetime
- 2001-11-02 DE DE60121794T patent/DE60121794D1/en not_active Expired - Lifetime
- 2001-11-02 AU AU2002218002A patent/AU2002218002A1/en not_active Abandoned
- 2001-11-02 US US10/000,752 patent/US20020128295A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002036109A3 (en) | 2003-05-30 |
US20020128295A1 (en) | 2002-09-12 |
EP1341532A2 (en) | 2003-09-10 |
EP1341532B1 (en) | 2006-07-26 |
DE60121794D1 (en) | 2006-09-07 |
ATE333868T1 (en) | 2006-08-15 |
WO2002036109A2 (en) | 2002-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200512016A (en) | Drug-coated stents and methods of use therefor | |
WO2002058684A3 (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
ATE430568T1 (en) | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING ATHEROSCLERosis, RESTENOSIS AND RELATED DISEASES | |
WO2002100433A1 (en) | Medicinal compositions | |
CA2380904A1 (en) | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer | |
NO995718L (en) | Herbal extract composition and method of innum "boosting" ability | |
WO2004006842A3 (en) | Combinations of drugs for the treatment of neoplasms | |
EP1140840A4 (en) | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
JO2373B1 (en) | W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | |
DE69317578D1 (en) | USE OF RILUZOLE FOR TREATING TRAUMATIC NEUROLOGICAL DAMAGES | |
DK0768885T3 (en) | Method of inhibiting cancer metastasis by oral administration of soluble modified citrus pectin | |
MX9705296A (en) | Novel compounds. | |
MY127898A (en) | Dual-release compositions of a cyclooxygenase-2 inhibitor | |
WO2001087306A8 (en) | Compositions and methods for the treatment of colorectal cancer | |
DE69738667D1 (en) | PREVENTATION AND TREATMENT OF COLONADOMENO OR COLONMICROADENOMA WITH 6-FLUORO-SODEOXYCHOLIC ACID | |
DE69526937D1 (en) | USE OF METHANBISPHOSPHONIC ACID DERIVATIVES FOR TREATING LOSSED PROSTHESES | |
AU2002218002A1 (en) | Use of pyridoxamine for the treatment and inhibition of obesity-related complications | |
MX9606503A (en) | Pla2 inhibitors and their use for inhibition of intestinal cholesterol absorption. | |
NZ304291A (en) | Trisubstituted phenyl derivatives, preparation and pharmaceutical compositions thereof | |
BG101875A (en) | New cryptoficins and method for their preparation | |
NZ332096A (en) | Alpha-hydroxylic acid derivatives their production and use in treating conditions requiring endothelin inhibition | |
AU8736798A (en) | Use of cholinesterase inhibitors for treating attention deficit disorders | |
NO20000446D0 (en) | Use of physiologically acceptable vanadium compounds, salts and complexes | |
WO2005089365A3 (en) | Treatment and prevention of abnormal cellular proliferation | |
AU8020698A (en) | Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain |